|
1
|
Van der Bruggen P, Traversari C, Chomez P,
Lurquin C, De Plaen E, Van den Eynde BJ, Knuth A and Boon T: A gene
encoding an antigen recognized by cytolytic T lymphocytes on a
human melanoma. Science. 254:1643–1647. 1991.
|
|
2
|
Ohman Forslund K and Nordqvist K: The
melanoma antigen genes - any clues to their functions in normal
tissues? Exp Cell Res. 265:185–194. 2001.PubMed/NCBI
|
|
3
|
Peikert T, Specks U, Farver C, Erzurum SC
and Comhair SA: Melanoma antigen A4 is expressed in non-small cell
lung cancers and promotes apoptosis. Cancer Res. 66:4693–4700.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bergeron A, Picard V, LaRue H, Harel F,
Hovington H, Lacombe L and Fradet Y: High frequency of MAGE-A4 and
MAGE-A9 expression in high-risk bladder cancer. Int J Cancer.
125:1365–1371. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bellati F, Napoletano C, Tarquini E,
Palaia I, Landi R, Manci N, Spagnoli G, Rughetti A, Panici PB and
Nuti M: Cancer testis antigen expression in primary and recurrent
vulvar cancer: association with prognostic factors. Eur J Cancer.
43:2621–2627. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim KH, Choi JS, Kim IJ, Ku JL and Park
JG: Promoter hypomethylation and reactivation of MAGE-A1 and
MAGE-A3 genes in colorectal cancer cell lines and cancer tissues.
World J Gastroenterol. 12:5651–5657. 2006.PubMed/NCBI
|
|
7
|
Napoletano C, Bellati F, Tarquini E, et
al: MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic
factors and effects of chemotherapy. Am J Obstet Gynecol.
198:99.e1–7. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vatolin S, Abdullaev Z, Pack SD, et al:
Conditional expression of the CTCF-paralogous transcriptional
factor BORIS in normal cells results in demethylation and
derepression of MAGE-A, and reactivation of other
cancer-testisgenes. Cancer Res. 65:7751–7762. 2005.
|
|
9
|
Lian Y, Sang M, Ding C, Zhou X, Fan X, Xu
Y, Lu W and Shan B: Expressions of MAGE-A10 and MAGE-A11 in breast
cancers and their prognostic significance: a retrospective clinical
study. J Cancer Res Clin Oncol. 138:519–527. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yamamoto H, Morimoto T, Sano M, Fukuda M,
Ueno E, Tajima T and Iwase T: Proposals for revisions of UICC TNM
system (1997) - breast cancer. Gan To Kagaku Ryoho. 25:1087–1093.
1998.(In Japanese).
|
|
11
|
Sugita M, Geraci M, Gao B, et al: Combined
use of oligonucleotide and tissue microarrays identifies
cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res.
62:3971–3979. 2002.PubMed/NCBI
|
|
12
|
Kufer P, Zippelius A, Lutterbüse R, et al:
Heterogeneous expression of MAGE-A genes in occult disseminated
tumor cells: a novel multimarker reverse transcription-polymerase
chain reaction for diagnosis of micrometastatic disease. Cancer
Res. 62:251–261. 2002.
|
|
13
|
Demonty G, Bernard-Marty C, Puglisi F,
Mancini I and Piccart M: Progress and new standards of care in the
management of HER-2 positive breast cancer. Eur J Cancer.
43:497–509. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Green CA, Peter MB, Speirs V and Shaaban
AM: The potential role of ER beta isoforms in the clinical
management of breast cancer. Histopathology. 53:374–380. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bai S, He B and Wilson EM: Melanoma
antigen gene protein MAGE-11 regulates androgen receptor function
by modulating the interdomain interaction. Mol Cell Biol.
25:1238–1257. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bai S and Wilson EM:
Epidermal-growth-factor-dependent phosphorylation and
ubiquitinylation of MAGE-11 regulates its interaction with the
androgen receptor. Mol Cell Biol. 28:1947–1963. 2008. View Article : Google Scholar : PubMed/NCBI
|
